← Back to patent-cliff list
结合雌激素/醋酸巴多昔芬
Tier C — Watch / tradeConjugated Estrogens/Bazedoxifene Acetate
辉瑞
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ERα、ERβ
Brand：Aprela、Duavee、Duavive
Indications (approved)：雌激素缺乏综合征、骨质疏松症、血管舒缩症
Regional status
US
批准上市
2013-10-03
EU
批准上市
2014-12-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Conjugated Estrogens/Bazedoxifene Acetate?
Approved indications include: 雌激素缺乏综合征, 骨质疏松症, 血管舒缩症.
When does the Conjugated Estrogens/Bazedoxifene Acetate patent expire?
No public expiry year is available for Conjugated Estrogens/Bazedoxifene Acetate yet; this page updates once verified.
How do I get a quote for Conjugated Estrogens/Bazedoxifene Acetate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24